AB-Biotics seeks partners at Vitafoods Europe to market its cholesterol-lowering and IBS probiotics

 Breaking News
  • Cargill’s European Poultry Business Expands into Poland Cargill has agreed to acquire Konspol, one of Poland’s leading value-added food companies, providing an array of products in the chilled convenience, frozen and cold cut categories. This acquisition marks the introduction of Cargill’s global protein business into the Polish market and strengthens the company’s global poultry footprint, expanding operations to 14 countries. Under the agreement, [...]...
  • Social Enterprise ‘Brewgooder’ Secures Biggest Ever Listing Scottish beer brand ‘Brewgooder’ has secured a new UK listing with Tesco that will significantly advance its mission to bring clean water access to one million people. Representing its biggest ever listing deal to date, the agreement will see the social enterprise supply single bottles of its popular Clean Water Lager to 481 Tesco stores [...]...
  • First Clean Label Liquid Margarine Bunge Loders Croklaan is launching Delica Pro Gold, its new, next-gen liquid margarine. The plant-based, clean-label margarine has been developed for artisanal and industrial bakeries. Delica Pro Gold is a liquid, non-hydrogenated margarine without E-numbers and contains no artificial colors or flavors. This innovative fat formula has exceptional functionality. “The real challenge was to create a liquid margarine [...]...
  • Global Aseptic Packaging to Grow 16% by 2022 The world market for aseptically packed products amounted to 152 billion litres in 347 billion packs during 2017, according to the new Global Aseptic Packaging report from leading food and drinks consultancy Zenith Global and packaging experts Warrick Research. Volumes have risen by 2.7% a year since 2012, with South East Asia achieving the fastest [...]...
  • Lactalis Expands in Infant Nutrition With €740 Million Acquisition Lactalis Group, the international dairy group based in Laval, France, is acquiring the Nutritional business of Aspen Pharmacare for €739.8 million (R12.9 billion). The business being acquired supplies a wide range of infant nutritional and growing-up milk products across both the premium and value segments. It manufactures and markets well established quality brands, including S-26, [...]...

AB-Biotics seeks partners at Vitafoods Europe to market its cholesterol-lowering and IBS probiotics

May 21
11:06 2012
  •  The Spanish biotech company looks for pharma or food companies interested in selling these IP-protected and clinically tested nutraceuticals, AB-LIFE and I3.1, in Europe and around the world

Barcelona (Spain).- The Spanish biotech company AB-Biotics presents these days at Vitafoods Europe, in Geneva, its  new probiotics AB-LIFE and I3.1, focused on the prevention and treatment of cholesterol and irritable bowel syndrome, respectively. The company wants to contact pharma or food companies interested in licensing these functional ingredients in the European. market and / or worldwide.

This important meeting is held in Geneva from 22th to 24th May. AB-Biotics wants to take advantage of this international showcase to look for licensors for two revolutionary probiotics. “The applications of AB-LIFE and I3.1 for the industry are very diverse, so in recent months several companies from different countries have already expressed interest in a possible license agreement”, said Sergi Audivert and Miguel Angel Bonachera, CEOs of AB-Biotics.


AB-LIFE: the first probiotic therapy in preventing cardiovascular disease

AB-BIOTICS is looking for pharmaceutical companies interested in licensing AB-LIFE in new markets. AB-LIFE is a nutritional ingredient which reduces cholesterol levels by 14%, according to clinical studies performed by Hospital Puerta del Hierro inMadrid. In addition to its greater efficacy, this new ingredient has another important difference in comparison with other solutions in the market: it not only reduces the levels of cholesterol ingested in the diet, but also blood cholesterol levels, leading to increased effectiveness in a larger number of people. 

With AB-LIFE, the Spanish company AB-BIOTICS has opened the door to probiotic therapy in preventing cardiovascular disease. As well as its possible use in the form of capsules, AB-LIFE can be added to foods with no thermal treatment, such as dairy products, or to drinks or juices using encapsulation techniques. AB-Biotics has already signed agreement agreements with different companies to distribute AB-LIFE in Southeast Europe, particularly in the markets of Slovenia, Croatia, Bosnia-Herzegovina, Serbia, Montenegro, Macedonia and Albania; and also Spain and Brazil.


I3.1: a better quality of life for IBS patients

Irritable Bowel Syndrome (IBS) is considered to be the most common gastrointestinal disorder. Its prevalence in western world is estimated to be 10-15% of the adult population. Current treatments for IBS have limited efficacy and severe side effects have been reported in recently approved drugs. AB-BIOTICS has developed I3.1, the first probiotic formula which produces a global improvement of quality of life in IBS patients.

I3.1 consists of a combination of three lactic acid bacteria, more precisely two Lactobacilli and one Pediococcus. Strains in I3.1 formula are able to produce high amounts of short chain fatty acids, especially, butyric acid. SCFAs are readily absorbed by intestinal mucosa and are known to stimulate serotonin release, which modulates both gut motility and sensation. Therefore, in situ production of SCFAs by strains of the I3.1 formula is useful to modulate gut motility and reduce visceral pain. Moreover, I.31 has displayed significant anti-inflammatory activity in two different animal models of gut inflammation, reducing both external symptoms of IBS and molecular markers. Also, 3.1 displays a significant inhibitory activity against many pathogenic bacterial strains, while allowing the growth of common commensal bacteria of the human gastrointestinal flora. Clinical trial has confirmed that I3.1 makes a positive improvement in health-related quality of life of IBS patients, reducing gastrointestinal discomfort and pain. “AB-BIOTICS is looking for pharmaceutical companies interested in licensing I3.1 in different markets –said Sergi Audivert and Miquel Àngel Bonachera, CEOs of AB-BIOTICS-. The product can be dosed both in capsules, tablets and sachets, with a product stability of at least 2 years”.



AB-BIOTICS is a Spanish biotechnology company focused on research, development, protection and distribution of its own exclusive biotechnological solutions.  The company’s mission is to improve the health and wellbeing of people. The company has an innovative philosophy and its own know-how that allows it to develop avant-garde products with high added value for the market.

 Since 2010, ABBIOTICS is listed in the Alternative Investment Market (MAB, in Spanish). The company has just started its international expansion plan, in order to reinforce their commercial activity and be present in high-potential countries like theUnited States, theUnited Kingdom,Germany,France,Turkey,Mexico andBrazil.


More information: http://www.ab-biotics.com/
Nuria Peláez – Communications officer
0034 654 352 541

About Author



Related Articles

Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • September 25, 2018PPMA Show 2018
  • September 27, 2018Int'l Fruit Show (eurofruit)
  • September 30, 2018Trade Fair for Butchers, Caterers and Meat Industry (Meat Expo)
  • October 1, 2018Poznan International Fair
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber

Subscribe Here